Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419341 · ClinicalTrials.gov registry record · Phase 3
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
A Phase 3 study of Primary Immune Deficiency, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
- 13
- Study locations
NCT00419341 is a Phase 3 study of Primary Immune Deficiency that has completed, run by CSL Behring. The registered enrollment target is 49 participants, below the 1,195-participant average among 5 other Primary Immune Deficiency trials with a reported enrollment target (96% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT00419341, a Phase 3 study of Primary Immune Deficiency, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
Conditions Studied
Interventions
- BIOLOGICAL Human Normal Immunoglobulin for Subcutaneous Administration
Study Locations (13)
California
- Study Site - Los Angeles
- Study Site - Los Angeles
Indiana
- Study Site - Fort Wayne
- Study Site - Indianapolis
Colorado
- Study Site - Centennial
Florida
- Study Site - North Palm Beach
Georgia
- Study Site - Atlanta
Iowa
- Study Site - Iowa City
Missouri
- Study Site - St Louis
New Jersey
- Study Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419341
The ClinicalTrials.gov registry entry for NCT00419341 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,195-participant average among 5 other Primary Immune Deficiency trials with a reported enrollment target (96% lower). The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immune Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Human Normal Immunoglobulin for Subcutaneous Administration is the first listed.
NCT00419341 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Indiana, Colorado.
Frequently Asked Questions
What is clinical trial NCT00419341 about?
NCT00419341 is a clinical study titled "Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy". The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
What is the current status of trial NCT00419341?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2006-11. Estimated completion is 2008-10.
What conditions does trial NCT00419341 study?
This clinical trial studies the following conditions: Primary Immune Deficiency.
What interventions are being tested in trial NCT00419341?
The interventions under investigation include: Human Normal Immunoglobulin for Subcutaneous Administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT00419341?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419341 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
ACTIVE NOT RECRUITING · Phase 3
-
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
ACTIVE NOT RECRUITING · Phase 3
-
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
RECRUITING
-
Biologics And Clinical Immunology Cohort at Sinai
RECRUITING
-
COVID-19 Vaccine Responses in PIDD Subjects
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.